Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CELZ

Creative Medical Technology Holdings Inc

Apr 29 • 03:17PM ET

2.19

-0.04 -1.79 %

Healthcare • Biotechnology • USA • Nano • NASD

Apr 28, 9:06 AMCreative Medical Technology's Ultrasome therapy meets primary endpoint in knee osteoarthritis pilot with 93% response rate

Peers: VXRT HOOK ATOS CLRB CYCN DYAI MBRX AIXC

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.29	Insider Own	0.95%	Shs Outstand	3.70M	Perf Week	-2.23%
Market Cap	8.09M	Forward P/E	-	EPS next Y	-1.43	Insider Trans	0.00%	Shs Float	3.66M	Perf Month	12.89%
Enterprise Value	0.89M	PEG	-	EPS next Q	-0.39	Inst Own	3.49%	Short Float	4.28%	Perf Quarter	4.78%
Income	-6.00M	P/S	809.22	EPS this Y	40.48%	Inst Trans	1.66%	Short Ratio	3.45	Perf Half Y	-57.43%
Sales	0.01M	P/B	1.08	EPS next Y	4.67%	ROA	-82.81%	Short Interest	0.16M	Perf YTD	11.73%
Book/sh	2.03	P/C	1.12	EPS next 5Y	-	ROE	-86.53%	52W High	6.25 -64.96%	Perf Year	8.42%
Cash/sh	1.95	P/FCF	-	EPS past 3/5Y	35.28% 66.83%	ROIC	-79.78%	52W Low	1.50 45.61%	Perf 3Y	-66.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-59.24% -48.43%	Gross Margin	-1992.02%	Volatility	7.36% 9.12%	Perf 5Y	-99.05%
Dividend TTM	-	EV/Sales	89.22	EPS Y/Y TTM	38.17%	Oper. Margin	-102380.23%	ATR (14)	0.17	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	25.97	Sales Y/Y TTM	-45.45%	Profit Margin	-99916.80%	RSI (14)	51.69	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	25.97	EPS Q/Q	54.52%	SMA20	-1.16%	Beta	1.86	Target Price	20.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	0.00%	SMA50	8.53%	Rel Volume	0.67	Prev Close	2.23
Employees	4	LT Debt/Eq	0.00	Earnings	Feb 25	SMA200	-16.65%	Avg Volume	45.43K	Price	2.19
IPO	Nov 06, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	-97.30% -	Trades		Volume	27,171	Change	-1.79%

Apr-28-26 09:01AM	Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies (GlobeNewswire)
Feb-10-26 09:00AM	Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline (GlobeNewswire)
Jan-13-26 09:15AM	Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain (GlobeNewswire) -11.22%
Jan-06-26 09:15AM	Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative (GlobeNewswire) +9.31%
Dec-17-25 09:15AM	Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point (GlobeNewswire)
09:15AM	Loading…
Dec-02-25 09:15AM	Creative Medical Technology Holdings Announces World Health Organization Approval of "olastrocel" as INN for Lead Allogeneic Cell Therapy CELZ-201 (GlobeNewswire) -11.75%
Nov-05-25 09:55AM	Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now (Zacks)
Oct-30-25 09:15AM	Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits (GlobeNewswire) -13.03%
Oct-29-25 09:00AM	Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds (GlobeNewswire) -32.74%
Oct-27-25 08:15AM	Creative Medical Technology Holdings Issues Letter to Shareholders (GlobeNewswire) +5.43%
Oct-07-25 09:15AM	Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs (GlobeNewswire)
Aug-13-25 09:01AM	Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain (GlobeNewswire)
Jul-31-25 05:43AM	New Strong Sell Stocks for July 31st (Zacks)
Jul-17-25 09:15AM	Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells (GlobeNewswire)
Jul-11-25 08:01AM	Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling (GlobeNewswire)
12:00PM	Loading…
Mar-25-25 12:00PM	Creative Medical Technology Holdings, Inc. (CELZ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -16.67%
09:40AM	Is Creative Medical Technology Holdings, Inc. (CELZ) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-20-25 07:50AM	Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain (GlobeNewswire) -8.25%
Mar-06-25 08:10AM	Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds (GlobeNewswire) -29.30%
Feb-20-25 08:00AM	Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential (GlobeNewswire)
Feb-14-25 07:00AM	Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem (GlobeNewswire)
Feb-11-25 09:25AM	Creative Medical Technology Reports Positive One-Year Results for AlloStem Type 2 Diabetes Program (GlobeNewswire)
Feb-05-25 08:25AM	Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development (GlobeNewswire)
Jan-30-25 09:25AM	Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain (GlobeNewswire) +5.30%
Nov-13-24 09:00AM	Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment (GlobeNewswire)
Oct-24-24 08:21AM	Creative Medical to sell 418,552 shares at $4.42 in registered direct offering (TipRanks)
Oct-23-24 08:00AM	Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -22.57%
Jul-24-24 09:00AM	Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program (GlobeNewswire)
Jul-10-24 08:30AM	Creative Medical Technology Holdings Provides Corporate Update (GlobeNewswire)
Jun-24-24 08:30AM	Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin (GlobeNewswire)
10:54AM	Loading…
May-13-24 10:54AM	CELZ Stock Earnings: Creative Medical Tech Beats EPS for Q1 2024 (InvestorPlace)
Mar-27-24 09:00AM	Creative Medical Technology Holdings Provides Corporate Update (Business Wire)
Mar-07-24 11:04AM	Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101 (Zacks) +32.35%
09:15AM	Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access (Business Wire)
Mar-06-24 07:00AM	Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy (Business Wire) +15.28%
Dec-20-23 09:35AM	Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain (ACCESSWIRE)
Nov-15-23 08:00AM	Creative Medical Technology Holdings Provides Corporate Update (PR Newswire)
Oct-10-23 08:00AM	Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine using AlloStem ('CELZ-201-DDT') Novel Cell Therapy to Treat Chronic Lower Back Pain (PR Newswire)
Sep-19-23 08:00AM	Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain (PR Newswire)
Aug-24-23 10:45AM	What Is Allogeneic Cell Therapy, And Whats Driving This Markets 25%+ Annual Global Growth? (ACCESSWIRE)
Jul-13-23 09:00AM	Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update (ACCESSWIRE) -5.84%
Jun-28-23 08:00AM	Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements (PR Newswire)
Jun-12-23 08:01AM	Creative Medical Technology Announces $2 Million Share Repurchase Program (PR Newswire)
08:00AM	Creative Medical Technology Holdings Provides Corporate Update (PR Newswire)
Jun-09-23 12:30PM	Creative Medical Technology Holdings Announces Reverse Stock Split (PR Newswire) -24.96%
May-31-23 08:00AM	Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform (PR Newswire)
May-22-23 08:30AM	Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development (PR Newswire)
May-18-23 08:00AM	Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem Allogenic Cell Line (PR Newswire) -10.29%
May-14-23 08:13AM	Creative Medical Technology Holdings First Quarter 2023 Earnings: US$0.075 loss per share (vs US$0.18 loss in 1Q 2022) (Simply Wall St.)
Apr-12-23 08:00AM	Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study (PR Newswire) +80.79%
Apr-04-23 08:00AM	Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update (PR Newswire)
Mar-23-23 08:00AM	Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes (PR Newswire) +5.77%
Mar-21-23 08:00AM	Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development (PR Newswire) +15.74%
Mar-07-23 08:00AM	Creative Medical Technology Holdings Engages Highly Respected International CRO for Phase 1 / 2 Clinical Trial to Treat Type 1 Diabetes Using CELZ-201 (Business Wire)
Feb-14-23 08:00AM	Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects (Business Wire) +10.82%
Feb-08-23 08:00AM	Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes (PR Newswire) +101.04%
Nov-03-22 07:30AM	Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (PR Newswire) +24.84%
Oct-20-22 08:00AM	Creative Medical Technology Holdings Develops AlloStem Clinical Cell Line (PR Newswire) +5.49%
Sep-26-22 08:00AM	Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study (PR Newswire) -11.43%
Jul-28-22 07:30AM	Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study (PR Newswire) +8.53%
Jun-15-22 08:30AM	Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform (PR Newswire)
Apr-29-22 08:40AM	Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) -6.00%
Apr-20-22 08:30AM	Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product (PR Newswire) +9.38%
Apr-12-22 08:30AM	Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World (PR Newswire) -7.08%
Mar-31-22 08:30AM	Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz® Supercharged Autologous Immunotherapy Platform (PR Newswire) +15.04%
Mar-23-22 08:30AM	Creative Medical Technology Announces Positive Top-Line Results for StemSpine® Pilot Study (PR Newswire) +82.35%
Mar-10-22 08:30AM	Creative Medical Technology Secures Exclusive Distribution Rights for Cervos Medical's Marrow Cellution Devices for Use in Urology, Gynecology, and Male and Female Sexual Dysfunction (PR Newswire)
Mar-08-22 08:30AM	Creative Medical Technology to Participate in the 34th Annual Roth Conference (PR Newswire) -10.74%
Mar-02-22 08:30AM	Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer (PR Newswire)
Jan-20-22 07:15AM	Phoenix's Creative Medical Technology uplists to Nasdaq in hopes of making more stem cell treatments (American City Business Journals)
Nov-09-21 04:45PM	Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market (PR Newswire) -7.08% -6.07%
Oct-12-21 08:15AM	Creative Medical Technology Holdings Reports Positive Data on ImmCelz Immunotherapy Product (PR Newswire)
Oct-01-21 08:15AM	Creative Medical Technology Holdings Files Provisional Patent on Novel Type 1 Diabetes Immunotherapy Using Exosomes from MyeloCelz Platform (PR Newswire) +14.00%
Sep-16-21 07:45AM	Creative Medical Technology Holdings, Inc. Engages Established Contact Management Organization to Accelerate Adoption of CaverStem® (PR Newswire) +5.06%
Aug-09-21 04:43PM	Creative Medical Technology Holdings Announces $3.8 Million Private Placement with Institutional Investors (PR Newswire) +27.84%
Jul-20-21 07:45AM	Creative Medical Technology Holdings Announces MyeloCelz The Company's Second Regenerative Immunotherapy Product (PR Newswire)
Jun-22-21 07:45AM	Creative Medical Technology Holdings Recruits Renowned Stem Cell Clinical Trials Expert to Hyper-Accelerate FDA Clearance (PR Newswire)
Jun-17-21 07:00AM	Creative Medical Technology Holdings To Present ImmCelz® Subsidiary At World Stem Cell Conference (PR Newswire) +6.67%
Jun-09-21 08:18AM	Creative Medical Technology Holdings Identifies Synergy Between ImmCelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes (PR Newswire) +17.12%
May-24-21 07:45AM	Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease (PR Newswire) +10.94%
May-20-21 08:45AM	Internationally Renowned Clinician Scientist Camillo Ricordi Head of Diabetes Research Institute Joins Creative Medical Technology Holdings (PR Newswire) +17.88%

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Its products include CaverStem, FemCelz, StemSpine and ImmCelz. The company was founded by Timothy Warbington on December 3, 1998 and is headquartered in Phoenix, AZ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CELZ

Creative Medical Technology Holdings Inc

Upgrade your Finviz experience